Short Sellers Retreat From Biotech Stocks Again

Photo of Trey Thoelcke
By Trey Thoelcke Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Stocks in this industry continue to be hot, but short sellers shied away from many of them in late February. Those bucking that trend include BioMarin Pharmaceutical, which got FDA and CHMP approval for Vimizim during the period, and Medivation, which said it swung to a profit.

Amgen Inc. (NASDAQ: AMGN) saw a 5.3% decrease in late February to 10.15 million shares, or 1.3% of the total float. That was the second highest level of short interest so far this year. It would take about three days to close out all short positions.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) saw a 7.6% rise in its short interest to around 6.78 million shares. That was the greatest number of shares short since last March, and it was 4.7% of the total float. The days to cover remained less than five.

Celgene Corp. (NASDAQ: CELG) saw its short interest decline by 7.9% to more than 4.57 million shares, or 1.1% of Celgene’s float. Before that, the short interest had been rising since the end of December. It still would take less than two days to cover all short positions.

Dendreon Corp. (NASDAQ: DNDN) saw its short interest shrink to 44.13 million shares from the 44.94 million in mid-February. The number of shares sold short has dwindled for nine straight periods to the lowest level in at least a year, but it still represents 29.4% of the float. And note that the days to cover is about 20.

Gilead Sciences Inc. (NASDAQ: GILD) had a 0.4% rise to 87.60 million shares short. That was the highest level of short interest in the past year, after rising in 10 of the past 11 periods. It totaled 5.7% of the total float. The days to cover rose to about eight.

Medivation Inc. (NASDAQ: MDVN) saw the biggest gain in short interest among the biotech companies featured here, 10.6%, to more than 3.47 million shares by the end of the month. That more than reclaimed the decline in the previous period, and it totaled 4.7% of the company’s float. It would take less than two days to close out all short positions.

Other biotech companies that saw a decrease in their short interest between the February 14 and February 28 settlement dates include Alexion Pharmaceuticals, Illumina, Incyte, Pharmacyclics, Questcor Pharmaceuticals, Regeneron Pharmaceuticals and Vertex Pharmaceuticals. On the other hand, the number of shares sold short in Biogen Idec and Seattle Genetics swelled somewhat during the period.

Photo of Trey Thoelcke
About the Author Trey Thoelcke →

Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.

Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.

Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.

Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618